iiinova — where your digital self keeps evolving

Guillaume P. Andrieu @guillaumeandrieu.bsky.social · 09/10/2026

Vous avez envie de mieux comprendre les leucémie et comment on se bat contre elle ? Demain pour la #FêteDeLaScience, nous animons un atelier à l’Institut Necker-Enfants Malades @inem-necker.bsky.social 📅 Sam. 10 oct., 10h-16h30 📍160 rue de Vaugirard 75015 Paris

000

Reposted by Guillaume P. Andrieu

eshaematology.bsky.social @eshaematology.bsky.social · 26/08/2026

📣 PROGRAMME HIGHLIGHT OF #ESHALL2027 3 SIMULTANEOUS MEET THE EXPERT SESSIONS 5th Translational Research Conference ACUTE LYMPHOBLASTIC LEUKAEMIA May 20-22, 2027/Malahide (Dublin), Ireland Chairs: K. Bernt, N. Boissel, J.Cools, U. Wartiovaara-Kautto More info ➡ bit.ly/49y6IaH #ESHCONFERENCES #LEUsm

101

Guillaume P. Andrieu @guillaumeandrieu.bsky.social · 02/09/2025

Happy to share our study published in @bloodjournal.bsky.social 🧬✂️🛑 We report that intragenic deletions of LEF1 generate a dominant-negative isoform and confer a targetable dependence on the Wnt/β-catenin pathway in T-ALL Full story 👉: doi.org/10.1182/bloo...

doi.org

LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALL

Key Points. LEF1 intragenic deletion is the most frequent LEF1 alteration in T-ALL and leads to a dominant-negative isoform.LEF1 intragenic deletion confer

120

Guillaume P. Andrieu @guillaumeandrieu.bsky.social · 19/03/2025

A fantastic program, insightful discussions, and exciting perspectives coming from the @helloeacr.bsky.social EACR Conference ‘Persister Cells’ on how to better identify, characterize and target drug-tolerant persister cells to leverage the treatment of bacterial infections and cancers.

000